In this podcast, I (@aging_scientist) spoke with Dr. Rich Miller about the ins and outs of mouse aging.
The topics we discussed, roughly in this order, included the Interventions Testing Program, rapamycin, mecilizine, and other lifespan-extending drugs. We talked about the importance of genetically heterogenous mouse stocks and the issues with fast-aging progeroid mouse models. We also covered his more recent work on aging rate indicators and the difference between classic biomarkers and aging rate indicators. Finally, we talked about the importance of lifespan research, misuse of the word healthspan, and the emerging use of frailty indices in mice.
VitaDAO and Kamil Pabis, MSc (the @Aging_Scientist on Twitter) bring this podcast to you.
Slowing aging by a couple of percents would save more money than curing any single disease, be it cancer, heart disease, or diabetes. Aging is, in fact, the major risk factor that all these diseases have in common. For this reason, slowing aging becomes the most efficient path to a sustainable and healthy future for humanity.
To get this message out we started The Aging Science podcast. We will bring you interviews and frank conversations with leading experts in the field of longevity, as well as evidence-based health advice to support you on this journey.
This podcast is brought to you by VitaDAO and Kamil Pabis, MSc (the @Aging_Scientist on Twitter).
In this podcast, I (@aging_scientist) had the pleasure of interviewing Asst. Prof Alaattin Kaya (@akay_lab).
We talked about recent breakthroughs in the field, the difficulties of getting funding for risky and novel research, funding agencies, “fishing expeditions”, the importance of overexpression genetic screens in aging research, novel mechanisms of action, and the replication crisis.
Insights on Grant-making and Systemic Change: Lessons from Impetus and Beyond with Martin Borch Jensen & Lada Nuzhna.
Outline:
0:00 What is Impetus and how did it get started?
3:12 Takeaways from running and creating Impetus Grants
5:04 Playbook for starting a grant-making program.
12:29 Common misunderstandings between the private sector and academia about funding.
14:12 The role of academia in publishing negative results
23:18 The most impactful levers for systemic change.
Dr Joris Deelen leader at the Max Planck for Biology of AGeing since 2020 and is passionate about research on human aging.
Matt Yousefzadeh, Ph.D., is a postdoctoral fellow in the laboratory of Dr. Laura Niedernhofer, Director of the Institute for the Biology of Aging and Metabolism at the University of Minnesota. He is interested in the mechanisms by which endogenous DNA damage and cellular senescence drive aging.
Dr. Mathieu is a co-founder and the acting Chief Executive Officer of Sentinel Environmental where they are building better microbiomes. Co-founder of Advanced Microbiotics, a startup focused on developing therapeutics to combat antibiotic-resistant bacteria. Did his Ph.D. in environmental engineering at Rice University.
Allison Duettmann is the president of Foresight Institute, a non-profit to advance biotech, nanotech, computing for the long-term benefit of life.
Dr. Shahaf Peleg is an Independent group leader, Metabolism and epigenetics in aging, FBN (Rostock)
Meet Tim Peterson - VitaDAO Longevity Steward, Faculty member at Washington University in St. Louis School of Medicine and co-founder of Healthspan Technologies and BIOIO
Tyler Golato is a Biogerontologist, and creative thinker building a more collaborative and open future. He co-founded Molecule and serves as Chief Scientist. He also co-initiated VitaDAO and PsyDAO and is focused on trying to develop new and innovative ways to improve funding processes in drug discovery and development.
Prof. Andrea B Maier - Longevity Medicine Physician, Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, Co-Director Centre for Healthy Longevity, @Age, National University of Singapore, Vrije Universiteit Amsterdam
Richard is a graduate of King’s (BSc, 1993 and PhD, 1996) and following postdoctoral research in the Department of Medicine, University of Cambridge, he joined the School of Cardiovascular Medicine & Sciences at King's as a Lecturer in Nov 2001. He was previously Faculty Vice-Dean (International) between Feb 2017 and Dec 2018 and is currently Faculty Lead for the College Service Committee.
Evandro F. Fang is a molecular gerontologist, leading an international anti-aging laboratory at the University of Oslo; his team is composed of 15+ trainees from 7+ countries. He did his PhD with Chair Professor Tzi Bun Ng at the Chinese University of Hong Kong on anti-cancer drug development (Jan. 2009-Dec.)
Join Aubrey de Grey and Vitalik Buterin on our fireside chat where they discuss and answer questions at the intersection of longevity and web3. The AMA is hosted by VitaDAO - VitaDAO is the world’s first decentralized intellectual property collective. Its mission is to extend the human lifespan by collectively financing and commercialising longevity therapeutics in an open and democratic manner. VitaDAO and its members will own the intellectual property assets that result from the projects it supports. Members can contribute work or funds to join VitaDAO by purchasing or earning VITA tokens.
Meet Laurence Ion - VitaDAO Dealflow Steward, Entrepreneur, longevity advocate and investor.
Laurence Ion: https://twitter.com/longevion
0:00 Who are you? What do you do for VitaDAO?
1:02 What fascinates you besides the DAO culture specifically?
3:39 Why did you choose to become a member of a DAO?
5:24 How did you get into the Web3 space?
7:08 What makes DAOs different?
9:27 What is a usual day for you in the DAO?
10:48 How did you choose to contribute to VitaDAO?
12:41 How long have you been in the Longevity Industry?
13:17 Why Longevity?
16:15 Describe the VitaDAO Community
17:51 Where do you see VitaDAO 5 to 10 years from now?
21:04 How is a DAO different from a company?
Prof. Brian Kennedy is an internationally recognized researcher in the aging field and the Director at the Centre for Healthy Longevity at NUS Medicine. His current focus is on translating and testing rejuvenation interventions in humans - to compress morbidity and extend healthy lifespan.
Qiao Wang is a core contributor at AllianceDAO best place to start a Web3 company. He is a believer in decentralized technologies such as cryptocurrencies that shift the balance of power from the elite to the commoner - additionally he is also a big advocate of longevity research as he loves life.
Dr. Emil Kendziorra is a founder and CEO at Tomorrow Biostasis GmbH based in Berlin, Germany and President of the Board at European Biostasis Foundation, a non-profit research foundation in Switzerland.
00:00 Intro
03:50 What is “Cryopreservation”?
06:58 State of Technology
13:00 When and why opt for “Cryopreservation”?
17:12 Important considerations
20:03 What does Tomorrow Biostasis do?
22:15 CryoDAO
22:55 What we are looking for?
23:35 The impact of getting involved in Cryopreservation
24:27 Q&A
Michael Baran, MBA, Ph.D. is Executive Director, WRDM, and Partner at Pfizer Ventures. Mike is responsible for identifying, evaluating, making, and managing equity investments aligned with the future directions of Pfizer.
This talk is part of the 2nd VitaDAO Crypto meets Longevity Symposium!
00:00 Intro
01:47 Creative destruction of Venture Capital
02:20 The trend toward Decentralization
05:29 The future of VC will be Decentralized
08:56 DeSci gaining recognition in mainstream scientific forums
10:01 Pfizer focus
13:19 2021 Longevity clinical trials
15:57 Longevity dealflow
18:05 DeSci: The path to 2030 & beyond
21:15 Q&A
VitaDAO Longevity Journal Club - Can young gut bacteria help you act younger?
Hosts: Estéfano Pinilla & Ariella Coler-Reilly
Guests: Katie Guzzetta & Marcus Böhme
